Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice

There is a critical need for therapeutic agents that can target the amino-terminal domain (NTD) of androgen receptor (AR) for the treatment of castration-resistant prostate cancer (CRPC). Calmodulin (CaM) binds to the AR NTD and regulates AR activity. We discovered that Hydrazinobenzoylcurcumin (HBC...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Wu, Min, Kim, Sahn-Ho, Datta, Indrani, Levin, Albert, Dyson, Gregory, Li, Jing, Kaypee, Stephanie, Swamy, M. Mahadeva, Gupta, Nilesh, Kwon, Ho Jeong, Menon, Mani, Kundu, Tapas K., Reddy, G. Prem-Veer
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2015
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4467427/
https://ncbi.nlm.nih.gov/pubmed/25704883
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky